Analyst firms · Leerink Partners · ILMN

Leerink Partners ILMN price target and rating history

Illumina Inc. (ILMN) · Health Care

Leerink Partners rates Illumina Inc. (ILMN) Outperform with a $270 price target, as of its latest action on Oct 4, 2022. It has published 5 rating actions on ILMN since August 2021, including 1 upgrade and 1 downgrade. Across 5 firms with a ILMN price target in the last 12 months, the median target is $185.

Current rating
Outperform
Price target
$270
Median target, all firms
$185
Actions on ILMN
5

Leerink Partners price target on ILMN

$430$350$27020222023202420252026
Leerink Partners price target on ILMN, each point a stated target, August 2021 to October 2022.

Every Leerink Partners rating on ILMN

How other firms rate ILMN

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
StephensEqual-Weight$275Oct 23, 2026
UBSBuy$260Sep 9, 2026
BernsteinMkt Perform$185Jun 26, 2026
RBC Capital MarketsOutperform$170May 15, 2026
DaiwaOutperform$155May 14, 2026

Questions about Leerink Partners and ILMN

What is Leerink Partners's price target for ILMN?
Leerink Partners's latest stated price target for Illumina Inc. (ILMN) is $270, from its action on Oct 4, 2022.
What is Leerink Partners's rating on ILMN?
Leerink Partners rates ILMN Outperform, a bullish rating, as of Oct 4, 2022.
When did Leerink Partners last change its view on ILMN?
On Oct 4, 2022, Leerink Partners upgrades to Outperform from Mkt Perform, price target $220 to $270.
How does Leerink Partners's ILMN target compare with other analysts?
Across 5 firms with a ILMN price target in the last 12 months, the median target is $185.

More ILMN rating histories

All Leerink Partners ratingsILMN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.